Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Authors:
Open Access
- 3 July 2017
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 15 (7) , 491-494
Abstract
(2017). Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? Expert Review of Cardiovascular Therapy: Vol. 15, No. 7, pp. 491-494.Keywords
This publication has 27 references indexed in Scilit:
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With AlirocumabJACC, 2017
- Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid DrugsNew England Journal of Medicine, 2015
- Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)The American Journal of Cardiology, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- Limit to Benefits of Large Reductions in Low-Density Lipoprotein Cholesterol LevelsJAMA Internal Medicine, 2013
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol LevelsJACC, 2012
- Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein loweringJournal of Clinical Lipidology, 2012
- Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolNew England Journal of Medicine, 2012
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"Current Controlled Trials in Cardiovascular Medicine, 2001